Thermo Fisher Scientific is expected to report fiscal second-quarter 2026 earnings per share of $5.71, up 6.5% from $5.36 a year ago. The company has beaten Wall Street estimates in each of the last four quarters. For the full year, analysts project EPS of $24.84, an 8.6% increase from fiscal 2025, with further growth to $27.18 expected in fiscal 2027. TMO stock has risen 24% over the past 52 weeks, outperforming the S&P 500 and the Health Care Select Sector SPDR ETF. Analysts rate the stock a Strong Buy with an average price target of $593.24, implying 17.1% upside.
Thermo Fisher Scientific IncArticle reports expected EPS beat and analyst upgrades, positive for valuation
McDonald’s Corporation
NVIDIA Corporation